Pipeline Molecules

27

Total

2

Phase III

8

Phase II

27

Phase I

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Make selections below to find information based on tumor type studied. Results will appear below.

Click to Expand

Pipeline Molecules Overview | BioOncology

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase II

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Solid Tumor
  • Breast
  • Lung
  • Solid Tumor

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)c

 

  • Gastrointestinal

Emactuzumab (anti-CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

Selective estrogen receptor degrader (SERD)

(GDC-0810/ARN-810, RG6046)d

 

  • Breast

Vanucizumab (anti-ANG2-VEGF biMAb)

(RG7221)

 

  • Gastrointestinal
  • Solid Tumor

Phase I

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Solid Tumor
  • Breast
  • Lung
  • Solid Tumor

Antibody-drug conjugate

(RG7986)b

 

  • Hematologic

Antibody-drug conjugate

(RG7882)b

 

  • Gastrointestinal
  • Gynecologic

Anti-CD20/CD3 biMAb

(RG7828)

 

  • Hematologic

Anti-CD40 MAb

(RG7876)

 

  • Solid Tumor

Anti-CEA CD3 TCB MAb

(RG7802)

 

  • Solid Tumor

Anti-Ly6E ADC

(RG7841)b

 

  • Breast
  • Lung
  • Solid Tumor

Anti-OX40 MAb

(MOXR0916, RG7888)

 

  • Solid Tumor

Anti-TIGIT

(MTIG7192A, RG6058)

 

  • Solid Tumor

BET inhibitor

(TEN-010, RG6146)g

 

  • Hematologic
  • Solid Tumor

Cergutuzumab amunaleukin (anti-CEA-IL2v)

(RG7813)

 

  • Solid Tumor

ChK1 inhibitor

(GDC-0575, RG7741)a

 

  • Solid Tumor

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)c

 

  • Gastrointestinal

Emactuzumab (anti-CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

ERK inhibitor

(GDC-0994, RG7842)a

 

  • Solid Tumor

FAP-DR5 biMAb

(RG7386)

 

  • Solid Tumor

FAP-IL2v FP

(RG7461)

 

  • Solid Tumor

HIF1 alpha LNA

(RG6061)h

 

  • Gastrointestinal
  • Solid Tumor

IDO inhibitor

(GDC-0919, NLG919, RG6078)e

 

  • Solid Tumor

LSD1 inhibitor

(RG6016)f

 

  • Hematologic

MDM2 antagonist (4) prodrug

(RG7775)

 

  • Hematologic

Raf/MEK inhibitor

(CKI27, RG7304)c

 

  • Solid Tumor

Selective estrogen receptor degrader (SERD)

(GDC-0810/ARN-810, RG6046)d

 

  • Breast

Selective estrogen receptor degrader (SERD (2))

(GDC-0927/SRN-927, RG6047)d

 

  • Breast

Vanucizumab (anti-ANG2-VEGF biMAb)

(RG7221)

 

  • Gastrointestinal
  • Solid Tumor

aDeveloped in collaboration with Array BioPharma. bDeveloped in collaboration with Seattle Genetics. cDeveloped in collaboration with Chugai. dSeragon acquisition. eDeveloped in collaboration with NewLink Genetics. fDeveloped in collaboration with Oryzon Genomics, S.A. gTensha acquisition. hSantaris acquisition.